Results 61 to 70 of about 1,183 (178)

Characterization of fragment sizes, copy number aberrations and 4‐mer end motifs in cell‐free DNA of hepatocellular carcinoma for enhanced liquid biopsy‐based cancer detection

open access: yesMolecular Oncology, 2021
Circulating cell‐free DNA (cfDNA) fragmentomics, which encompasses the measurement of cfDNA length and short nucleotide motifs at the ends of cfDNA molecules, is an emerging field for cancer diagnosis.
Chao Jin   +17 more
doaj   +1 more source

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

open access: yesInternational Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto   +21 more
wiley   +1 more source

Multi-signal cell-free DNA analysis for cancer detection [PDF]

open access: yes, 2023
In this thesis, we explored the potential of circulating cell-free DNA (cfDNA) metrics for non-invasive cancer detection and therapy response prediction, leveraging whole genome sequencing (WGS) data. Our research was divided into two parts.
van der Pol, Ymke
core   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

open access: yesUroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

Circulating Tumor DNA in Neurofibromatosis Type 1: Translating Molecular Discovery into Clinical Surveillance

open access: yesDiagnostics
Neurofibromatosis type 1 (NF1) is a genetic tumor predisposition syndrome characterized by a substantial risk of developing peripheral nerve sheath tumors, including malignant peripheral nerve sheath tumors (MPNSTs), which occur in 8–13% of patients ...
Joanne Vanessa Vargas   +4 more
doaj   +1 more source

Saliva Liquid Biopsy for Detection of Oral and Systemic Diseases

open access: yesJournal of Periodontal Research, EarlyView.
This Review summarizes and discusses the biological foundations and major classes of salivary biomarkers, outlines collection methods and analytical protocols for saliva‐based liquid biopsy, and technological convergences driven by multi‐omics approaches, artificial intelligence, and point‐of‐care devices in the application of oral and systemic ...
Irene Choi   +10 more
wiley   +1 more source

Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium

open access: yesInternational Journal of Cancer, Volume 159, Issue 8, Page 1873-1883, 15 October 2026.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms ...
Christine Worthington   +105 more
wiley   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

open access: yesCytopathology, Volume 37, Issue 5, Page 438-448, September 2026.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati   +15 more
wiley   +1 more source

Early stage non–small cell lung cancer: Toward a risk‐adaptive paradigm in the era of biologic precision

open access: yesCA: A Cancer Journal for Clinicians, Volume 76, Issue 5, September/October 2026.
Abstract The clinical landscape of early stage non–small cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low‐dose computed tomography screening, the frequent detection of ground‐glass opacities, and a rising incidence among never‐smokers, the diagnostic center of gravity has shifted toward earlier, potentially ...
Chaoqi Zhang   +23 more
wiley   +1 more source

Exploring the Predictive Value of Circulating Cell-Free DNA Within a Multiparameter Panel for Hepatocellular Carcinoma Detection

open access: yesLife
Background: Hepatocellular carcinoma (HCC) is one of the most common and deadliest cancers worldwide. Alpha-fetoprotein (AFP), a widely used and accessible tumoral marker, has limited performance in the early detection of HCC among high-risk populations.
Ioana Manea   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy